Bioflavonoid Fisetin Treatment Prevents the High Fat Diet Induced Metabolic Syndrome in Wistar Rats

Aim: This study evaluates the efficacy of bioflavonoid Fisetin treatment in preventing High Fat Diet (HFD) -induced metabolic syndrome (MetS) in Wistar rats. Method: Thirty six male wistar rats (n=6) were divided into six groups: control (normal diet), HFD only, HFD-STZ (Streptozotocin (STZ) Group, HFD-STZ + low-dose bioflavonoid fisetin, HFD-STZ + high-dose bioflavonoid fisetin and Metformin group. After 6 weeks, parameters including body weight, fasting blood glucose, insulin resistance (HOMAIR, Homeostatic Model Assessment of Insulin Resistance), Alanine aminotransferase (ALT) & Aspartate aminotransferase (AST) and lipid profiles were assessed. Results: Fisetin bioflavonoid treated groups exhibited significantly lower weight gain, improved insulin sensitivity, reduced serum triglycerides (TG) and Low Density Lipoprotein-cholesterol, and attenuated hepatic steatosis compared to the HFD group. Conclusion: The findings suggest that bioflavonoid fisetin may effectively prevent HFD-induced metabolic syndromes through modulation of metabolic and inflammatory pathways.